Scarica l'app Stockscreener
48.09
1.01%
0.48
Dopo l'orario di chiusura:
48.23
0.14
+0.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Novo Nordisk Adr Borsa (NVO) Ultime notizie
Novo Nordisk (NVO) Receives Positive Opinion For Wegovy By European Medicines Agency - Finviz
Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema - Finviz
After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss - Benzinga
Novo Nordisk (NVO) Fell Following a Profit Warning Release - Finviz
Better Buy in 2026: Novo Nordisk or Intuitive Surgical? - Finviz
Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk - Finviz
UBS Reiterates Neutral on Novo Nordisk A/S (NVO) Despite Wegovy Dose Progress - Finviz
Novo Nordisk (NVO) Hit By Lowered Guidance - Finviz
Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars - Sahm
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval - Finviz
2 Predictions for Novo Nordisk in 2026 - Finviz
Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead - ts2.tech
European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy - Sahm
Novo Nordisk (NVO) experiences muted sentiment from analysts - MSN
Novo Nordisk (NVO) Experiences Muted Sentiment From Analysts - Finviz
Why Novo Nordisk Stock Topped the Market on Thursday - Finviz
Novo Nordisk (NVO) Partners With Indian Health-Tech Startup - Finviz
Argus Downgrades Novo Nordisk A/S (NVO) to Hold From Buy - Finviz
Analysts See Upside In Novo Nordisk A/S (NVO) Driven By Diabetes And Obesity Trends - Finviz
Why Novo Nordisk Stock Was Melting on Monday - Finviz
Novo Nordisk A/S (NVO): A Bull Case Theory - Finviz
Novo Nordisk's Latest Clinical Result Is Sending the Stock Plunging. Here's What Investors Need to Know. - Finviz
Why Novo Nordisk Stock Just Hit a 4-Year Low - Finviz
European Drugmakers And Banks Put ADRs In The Green - Finimize
Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 - Finviz
J.P. Morgan Reiterates a Buy Rating on Novo Nordisk (NVO) - Finviz
Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B - TradingView
NVONovo Nordisk ADR Earnings - Finviz
Novo Nordisk Wants FDA Nod For A Higher-Dose Wegovy - Sahm
Medicare Announces Price Cuts For 15 Drugs— Novo Nordisk's Wegovy And Ozempic To Cost $274 A Month - Sahm
Did Pfizer Just Say "Checkmate" to Novo Nordisk? - Finviz
Novo Nordisk Alzheimer's Miss Disappointing But Not Material, Analyst Says - Sahm
European ADRs Stay Put As Novo Nordisk Slides - Finimize
0.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):